PLK1 and melanoma: These analyses suggest that the antiproliferative and pro-inflammatory effects of RSK inhibitors, such as BI-D1870, BRD7389, PMD-026, AF007, and fisetin in previous melanoma studies (Salhi et al, 2015; Kosnopfel et al, 2017, 2023; Theodosakis et al, 2017; Sechi et al, 2018; Li et al, 2022) could be due to the unselective targeting of other kinases, such as PLK1 (Fig S1B).